What does JPHARMA do?

JPHARMA is filed with the CBE under the catch-all “Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten”. Also registered: commercial agency, shop, wholesaler. Private Limited, started on 19 September 2014, 2 establishments.

What is the address of JPHARMA?

The registered office of JPHARMA is located at Rue Tilleul Del Motte(BOD) 18, 4537 Verlaine.

Is JPHARMA still active?

Yes. According to the CBE (31 October 2026) JPHARMA is active, legal situation “Normale toestand”, started on 19 September 2014.

Is JPHARMA registered on Peppol?

Yes, JPHARMA is registered on the Peppol network with ID 0208:0562799542.

What is the enterprise number of JPHARMA?

The enterprise number of JPHARMA is BE0562799542.

When was JPHARMA founded?

JPHARMA was founded on 19 September 2014.

Is JPHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 19 September 2014; 5 annual accounts filed, latest fiscal year 2025; 2 establishments in the CBE.

How much profit did JPHARMA make in 2025?

JPHARMA posted a profit after taxes of € 3,475 in financial year 2025.

What is the revenue of JPHARMA?

As a small company, JPHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 37,138.

JPHARMA (Private Limited) - Verlaine - BE0562799542

Dossier JPHARMA, printed on 31 October 2026 from databakkes.be/en/0562799542/jpharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Figures corrected NBB

Corrected annual account filed for 2025.

Financials

Financial year 2025

JPHARMA from Verlaine, company number BE0562799542, closed financial year 2025 with a result of € 3,475 after tax. For that financial year JPHARMA recorded a gross margin of € 37,138 and equity of € 109,115. Compared with financial year 2024, the result moved from € 6,742 to € 3,475. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on September 25, 2026.

What it is worth Growing

€ 109,115

▲ 3% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 3,475

▼ 48% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 36,972

▼ 17% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 90,565.

People and assets in 2025

Vehicles and equipment

€ 2,991

▲ 10% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 27 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 169,957

▼ 3% vs 2024

€ 6,241 is repaid this year. At this pace the long-term loan is gone in ≈ 27 years.

Owed to suppliers

€ 14,026

▲ 139% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 11,649

▲ € 10,705 vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 43,613 Gross margin 2022: € 43,613 First fiscal year in the series	€ 31,617 Gross margin 2023: € 31,617 ▼ 28% vs 2022 (€ 43,613) Unfavourable step	€ 29,166 Gross margin 2024: € 29,166 ▼ 8% vs 2023 (€ 31,617) Unfavourable step	€ 37,138 Gross margin 2025: € 37,138 ▲ 27% vs 2024 (€ 29,166) Favourable step	▲ 27%
Profit after taxes	€ 38,432 Profit after taxes 2022: € 38,432 First fiscal year in the series	€ 18,585 Profit after taxes 2023: € 18,585 ▼ 52% vs 2022 (€ 38,432) Unfavourable step	€ 6,742 Profit after taxes 2024: € 6,742 ▼ 64% vs 2023 (€ 18,585) Unfavourable step	€ 3,475 Profit after taxes 2025: € 3,475 ▼ 48% vs 2024 (€ 6,742) Unfavourable step	▼ 48%
Equity	€ 80,314 Equity 2022: € 80,314 First fiscal year in the series	€ 98,899 Equity 2023: € 98,899 ▲ 23% vs 2022 (€ 80,314) Favourable step	€ 105,640 Equity 2024: € 105,640 ▲ 7% vs 2023 (€ 98,899) Favourable step	€ 109,115 Equity 2025: € 109,115 ▲ 3% vs 2024 (€ 105,640) Favourable step	▲ 3%
Total debts	€ 15,012 Total debts 2022: € 15,012 First fiscal year in the series	€ 19,232 Total debts 2023: € 19,232 ▲ 28% vs 2022 (€ 15,012) Unfavourable step	€ 229,516 Total debts 2024: € 229,516 ▲ € 210,284 vs 2023 (€ 19,232) Unfavourable step	€ 236,159 Total debts 2025: € 236,159 ▲ 3% vs 2024 (€ 229,516) Unfavourable step	▲ 3%
Cash	€ 28,972 Cash 2022: € 28,972 First fiscal year in the series	€ 47,638 Cash 2023: € 47,638 ▲ 64% vs 2022 (€ 28,972) Favourable step	€ 44,451 Cash 2024: € 44,451 ▼ 7% vs 2023 (€ 47,638) Unfavourable step	€ 36,972 Cash 2025: € 36,972 ▼ 17% vs 2024 (€ 44,451) Unfavourable step	▼ 17%
Land & buildings	-	-	€ 199,357 Land & buildings 2024: € 199,357 First fiscal year in the series	€ 193,983 Land & buildings 2025: € 193,983 ▼ 3% vs 2024 (€ 199,357) Unchanged	▼ 3%
Retained profit	€ 61,764 Retained profit 2022: € 61,764 First fiscal year in the series	€ 80,349 Retained profit 2023: € 80,349 ▲ 30% vs 2022 (€ 61,764) Favourable step	€ 87,090 Retained profit 2024: € 87,090 ▲ 8% vs 2023 (€ 80,349) Favourable step	€ 90,565 Retained profit 2025: € 90,565 ▲ 4% vs 2024 (€ 87,090) Favourable step	▲ 4%
Dividend	€ 14,286 Dividend 2022: € 14,286 First fiscal year in the series	€ 0 Dividend 2023: € 0 ▼ 100% vs 2022 (€ 14,286) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 0 Dividend 2025: € 0 Unchanged (€ 0) Unchanged
Bank debt	€ 0 Bank debt 2022: € 0 First fiscal year in the series	€ 0 Bank debt 2023: € 0 Unchanged (€ 0) Unchanged	€ 175,977 Bank debt 2024: € 175,977 Unchanged (€ 0) Unfavourable step	€ 169,957 Bank debt 2025: € 169,957 ▼ 3% vs 2024 (€ 175,977) Favourable step	▼ 3%
Balance sheet total	€ 95,326 Balance sheet total 2022: € 95,326 First fiscal year in the series	€ 118,130 Balance sheet total 2023: € 118,130 ▲ 24% vs 2022 (€ 95,326) Unchanged	€ 335,156 Balance sheet total 2024: € 335,156 ▲ 184% vs 2023 (€ 118,130) Unchanged	€ 345,274 Balance sheet total 2025: € 345,274 ▲ 3% vs 2024 (€ 335,156) Unchanged	▲ 3%

Key figures of JPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to JPHARMA?

What happened at JPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Sep 25, 2026 Corrected annual accounts filed for financial year 2025. filed late Source: NBB ↗
Sep 6, 2025 New establishment in Huy. KBO
Oct 1, 2014 New establishment in Verlaine. KBO
Sep 19, 2014 Start of the company according to the CBE. KBO

In short

From € 38,432 profit in 2022 to € 3,475 profit in 2025.

Paid € 22,667 in corporate taxes since 2022.

Best year ever: 2022, with € 38,432 profit.

Paid out € 14,286 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Tilleul Del Motte(BOD) 18

4537 Verlaine

2.378.278.860

Avenue de la Croix-Rouge 3 box M

4500 Huy

Active since 6 September 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0562.799.542

VAT number

BE 0562.799.542

Registered office

Rue Tilleul Del Motte(BOD) 18, 4537 Verlaine

Names & denominations

JPHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

19 September 2014

Peppol

Active · Active since 19 Sept 2025

Contact

jpharma.be [email protected]

Activities · NACE

Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg

Overige gespecialiseerde wetenschappelijke en technische activiteiten

Handelsbemiddeling in de groothandel in andere specifieke goederen

Overige niet-gespecialiseerde detailhandel

Groothandel in farmaceutische en medische artikelen

Detailhandel in dames-, heren-, baby- en kinderboven- en onderkleding en kledingaccessoires (algemeen assortiment)

Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen

Overige zakelijke dienstverlening, neg

View on CBE Public ↗ Annual accounts (NBB) ↗